Hormone receptor-positive breast cancer is commonly managed with endocrine therapies such as tamoxifen, aromatase inhibitors, or ovarian function suppressors—including goserelin and leuprorelin—in premenopausal women. These treatments effectively reduce estrogen activity to inhibit tumor progression. However, their associated side effects often include severe vasomotor symptoms characterized by debilitating hot flushes and night sweats that surpass the intensity typically experienced during natural menopause. These distressing symptoms frequently impair quality of life and compromise adherence to crucial cancer therapies.

Elinzanetant works through a cutting-edge mechanism targeting the neurokinin pathway. Neurokinin, a neuropeptide implicated in the pathogenesis of menopausal symptoms, triggers the thermoregulatory dysfunction responsible for VMS. By antagonizing neurokinin receptors, elinzanetant moderates the signaling cascade that precipitates hot flushes and night sweats. This mode of action is distinct from hormonal replacement strategies, allowing it to provide symptomatic relief without compromising hormonal manipulation essential to breast cancer management.

The OASIS 4 trial enrolled women aged 18 to 70 years who suffered from clinically significant VMS, defined as 35 or more moderate-to-severe episodes weekly attributable to hormone therapies. Participants were randomized to receive elinzanetant for a full year or placebo for the initial 12 weeks, followed by elinzanetant for the remainder of the study. This robust design permitted assessment of both short- and long-term efficacy, stratified by the type of concurrent endocrine therapy.

Analysis demonstrated marked reductions in the frequency of moderate-to-severe vasomotor episodes among women treated with elinzanetant across all endocrine subgroups. Notably, tamoxifen recipients experienced an average reduction of four episodes per day after just one week of treatment, with improvements progressing to eight fewer episodes after 12 weeks. The placebo group exhibited significantly smaller reductions, underscoring elinzanetant’s therapeutic superiority. Parallel improvements were consistently observed in patients receiving aromatase inhibitors or ovarian function suppressors.

Beyond frequency, elinzanetant effectively attenuated the severity of symptoms. Initially recorded severity scores hovered around 2.5 on a 0 to 3 scale—indicative of moderate-to-severe VMS. After 12 weeks, those on elinzanetant reported severity scores between 1.5 and 1.6, corresponding to mild-to-moderate symptoms. Placebo-treated participants remained in the moderate range. Importantly, these benefits persisted throughout the 52-week treatment period, suggesting durable efficacy.

The safety profile of elinzanetant was encouraging, with most adverse events being mild. Common side effects included diarrhea, fatigue, and somnolence. Serious adverse reactions were rare, highlighting the drug’s suitability for long-term use in this vulnerable population. The favorable risk-benefit ratio further supports its integration into supportive care paradigms for breast cancer patients experiencing endocrine therapy-induced VMS.

Professor Fatima Cardoso, who spearheaded the analysis and holds leadership roles in breast oncology research, emphasized the transformative potential of elinzanetant. She framed its approval as a landmark advancement, providing a first-in-class targeted option for VMS that transcends traditional symptomatic management. By mitigating vasomotor distress, the drug not only enhances patients’ quality of life but also bolsters treatment adherence, a determinant of oncologic outcomes.

Looking ahead, ongoing investigations aim to elucidate potential pharmacological interactions between elinzanetant and a spectrum of targeted agents commonly deployed alongside endocrine therapy, thereby broadening the eligible patient pool. Researchers also aspire to extend clinical evaluation to metastatic breast cancer cohorts and male breast cancer patients—populations excluded from the current trial but similarly susceptible to VMS.

While Bayer, the pharmaceutical company behind elinzanetant’s development and trials, has not announced plans to explore its use in other hormone-sensitive malignancies such as prostate cancer, it remains open to facilitating investigator-initiated research in these contexts. Such studies could pave the way for expanding the therapeutic indications of this promising agent beyond breast oncology.

Independent experts have hailed these findings as pivotal for clinical practice. Dr. Javier Cortés, chair of EBCC’s organizing committee, highlighted how elinzanetant’s efficacy across endocrine therapy modalities simplifies treatment decisions and enhances patient support. Its novel targeted mechanism coupled with minimal adverse effects represents a breakthrough in managing a symptom complex that has historically been challenging to treat in breast cancer survivors.

In conclusion, elinzanetant emerges as a beacon of hope for women grappling with the burdensome vasomotor symptoms induced by life-saving hormonal therapies. Its ability to provide consistent, sustained relief while maintaining a strong safety profile positions it to redefine supportive care standards and improve therapeutic adherence, thereby potentially enhancing long-term cancer outcomes.

Subject of Research: People

Article Title: (Not provided)

News Publication Date: (Not provided)

Web References: https://clinicaltrials.gov/study/NCT05587296

References:
[1] Professor Fatima Cardoso’s roles and previous positions as cited in content
[2] VMS severity scoring methodology as described in the trial

Image Credits: (Not provided)

Keywords: Breast cancer, Breast carcinoma, Cancer treatments, Cancer medication, Hormone therapy, Side effects, Medical treatments

Breast cancer treatment has witnessed unprecedented improvements in survival rates over recent decades, shifting the focus of oncological care toward not just prolonging life but enhancing the lived experience during treatment. Chemotherapy, despite its efficacy in targeting malignant cells, imposes significant physiological and psychological burdens, including fatigue, muscle atrophy, and emotional distress. These side effects can compromise patient outcomes and adherence to therapy. The new analysis addresses a critical knowledge gap: can patients safely and effectively incorporate exercise into their treatment regime to counter these adverse effects?

Previously, clinical guidelines and patient counseling commonly suggested initiating exercise post-treatment, largely because the impact of physical activity concurrent with chemotherapy remained insufficiently understood and sometimes viewed as risky. Patients frequently reported confusion or fear regarding whether movement could exacerbate symptoms or interfere with treatment efficacy. The systematic review and meta-analytic approach adopted by the research team shed light on this ambiguity by rigorously aggregating data from 21 randomized controlled trials encompassing over 3,000 women actively receiving chemotherapy for breast cancer.

What makes this study particularly robust is its inclusive examination of varied exercise modalities. Rather than isolating a singular intervention, it encompasses aerobic activities such as walking and cycling, strength or resistance training, and combined programs integrating both forms of exercise. Intriguingly, the meta-analysis revealed no superiority hierarchy; all forms produced significant, positive effects on patients’ quality of life metrics. This flexibility is medically and practically significant, as it enables personalized exercise prescriptions adapted to fluctuating energy levels and physical capacity, which are hallmark challenges during chemotherapy cycles.

The mechanistic underpinnings of how exercise confers these benefits during chemotherapy are complex and multifaceted. From a physiological standpoint, physical activity stimulates muscle protein synthesis and counters catabolic effects induced by cytotoxic agents. Aerobic conditioning enhances cardiovascular function, reducing fatigue and improving oxygen transport to tissues. In parallel, strength training helps preserve lean body mass critical for maintaining metabolic health and functional independence. Beyond the physical, engaging in regular movement modulates neuroendocrine pathways and inflammatory cytokines, attenuating mood disturbances and cognitive dysfunction commonly experienced during treatment.

LaShae D. Rolle, MPH, CPH, the study’s lead author and a predoctoral fellow, emphasized the paradigm shift in oncology care toward integrating supportive strategies as essential rather than ancillary. She noted that quality of life should be a central therapeutic objective throughout treatment, not an afterthought following completion of chemotherapy. This philosophy underlines a more holistic approach in cancer care. Furthermore, co-author Tracy Crane, Ph.D., RDN, highlighted that exercise need not be intimidating or prescriptive to the point of rigidity. Instead, safety, personalization, and realism are paramount, empowering patients to engage in movement aligned with their daily condition and preferences.

The study’s exclusive focus on women undergoing active chemotherapy distinctly separates it from research oriented toward cancer survivors post-treatment, addressing the unique challenges patients face during the intense, variable phases of chemotherapy. These challenges include fluctuating symptoms such as nausea, pain, and immunosuppression, which demand adaptable and responsive exercise regimens orchestrated in conjunction with clinical oversight. The authors advocate that exercise should be administered under professional guidance to optimize benefits while ensuring patient safety.

From an oncological clinical perspective, integrating exercise as a co-therapy may also favorably influence treatment adherence and potentially reduce dose reductions or delays often necessitated by debilitating side effects. The data suggest that exercise interventions can serve as a non-pharmacologic modality that complements cytotoxic and targeted therapies, enhancing patients’ physical resilience and psychological fortitude.

Moreover, the findings have implications for healthcare policy and cancer care frameworks globally. Incorporating exercise programs within treatment protocols could standardize supportive care practices, reinforcing the role of physical activity in managing treatment toxicity. Importantly, this could help bridge gaps in survivorship care planning and improve long-term survivorship outcomes by instilling physical activity habits during the most critical treatment phases.

The researchers also underscore that while exercise confers broad benefits, the individualized nature of cancer treatment necessitates tailored prescriptions sensitive to patient-specific variables such as age, cancer stage, comorbidities, and baseline fitness. This nuanced approach fosters adherence, reduces risk of injury, and maximizes therapeutic impact.

In conclusion, this landmark meta-analytic review decisively supports the integration of exercise into chemotherapy regimens for women with breast cancer, highlighting that movement—appropriately calibrated—can transform patient experiences and outcomes. This paradigm shift underscores exercise as a pivotal adjunct in comprehensive oncology care, moving physical activity from a peripheral recommendation to a cornerstone of therapeutic strategy.

Subject of Research: Exercise interventions and quality of life during chemotherapy in women with breast cancer
Article Title: The Impact of Exercise Interventions on Domains of Quality of Life in Women Diagnosed with Breast Cancers During Chemotherapy Treatment: A Meta-Analytics Review
News Publication Date: 25-Feb-2026
Web References: http://dx.doi.org/10.1016/j.lanhl.2026.100819
Image Credits: Sylvester Comprehensive Cancer Center
Keywords: Breast cancer, Physical exercise, Chemotherapy